Although wild-type KRAS is generally associated with a better prognosis than mutated KRAS in patients with CRC (26, 28, 43), the results of our study demonstrate additionally, for the first time, that those wild-type KRAS patients who were at risk of a poorer outcome (i.e. those with high Ang-2 levels) had a significant PFS benefit if they received vanucizumab treatment instead of bevacizumab. Here, KRAS is linked to colorectal carcinoma.